{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(20)"],"submitter":["Yang CY"],"pubmed_abstract":["To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18-87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator's Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month"],"journal":["Journal of clinical medicine"],"pagination":["6209"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9605350"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study."],"pmcid":["PMC9605350"],"pubmed_authors":["Chu CY","Hui RC","Chi MH","Chen CB","Lin SH","Lu CW","Wang CW","Lai PJ","Hwang YS","Huang YH","Chung WH","Lin JY","Tseng HC","Yang CY","Lee HE","Tsai MF","Chan TC"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study.","description":"To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18-87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator's Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T11:29:27.775Z","creation":"2025-04-04T11:29:27.775Z"},"accession":"S-EPMC9605350","cross_references":{"pubmed":["36294530"],"doi":["10.3390/jcm11206209"]}}